|
USP51 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.89113177842637E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.91104942770926E-12 |
| Normal-vs-Stage2 |
3.31280003429413E-10 |
| Normal-vs-Stage3 |
2.41939801526314E-12 |
| Normal-vs-Stage4 |
4.20774526332934E-14 |
| Stage1-vs-Stage2 |
4.045800E-01 |
| Stage1-vs-Stage3 |
2.088600E-01 |
| Stage1-vs-Stage4 |
6.084300E-03 |
| Stage2-vs-Stage3 |
9.160000E-02 |
| Stage2-vs-Stage4 |
8.515500E-03 |
| Stage3-vs-Stage4 |
1.778000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.17381668221606E-12 |
| Normal-vs-AfricanAmerican |
3.72300000051062E-07 |
| Normal-vs-Asian |
9.07596220400819E-12 |
| Caucasian-vs-AfricanAmerican |
3.397800E-01 |
| Caucasian-vs-Asian |
8.611600E-01 |
| AfricanAmerican-vs-Asian |
4.210800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.75757194856396E-12 |
| Normal-vs-Female |
4.96813701289511E-12 |
| Male-vs-Female |
7.807200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.07849318154285E-12 |
| Normal-vs-Age(41-60Yrs) |
4.8034909383432E-12 |
| Normal-vs-Age(61-80Yrs) |
6.19104767451972E-12 |
| Normal-vs-Age(81-100Yrs) |
1.341320E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.785800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.025400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.771400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.754800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.585000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.130000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.562800E-03 |
| Classical-VS-Follicular |
4.842600E-01 |
| Classical-VS-Other |
2.470800E-01 |
| Classical-VS-Normal |
2.2997048709783E-11 |
| Tall-VS-Follicular |
8.637600E-02 |
| Tall-VS-Other |
8.130800E-01 |
| Tall-VS-Normal |
1.84796622448857E-12 |
| Follicular-VS-Other |
3.646800E-01 |
| Follicular-VS-Normal |
1.160305185266E-11 |
| Other-VS-Normal |
4.178500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.78355158104205E-12 |
| Normal-vs-N1 |
1.35447209004269E-14 |
| N0-vs-N1 |
5.364000E-03 |
|
|
